who require mechanical ventilation; the incidence increases at least fivefold, and as much as 21-fold, among these patients [1, 3, 4] . In patients with pneumonia, the length of hospital stay is increased by 7-9 days if treated with appropriate antibiotics, although if the initial treatment is with an inappropriate antibiotic, this figure may increase further [4] .
Mortality rates among patients with nosocomial pneumonia are high; it is the most lethal hospital-acquired infection. Ventilator-associated pneumonia, which is defined as pneumonia that develops in an intubated patient after 48 hours of mechanical ventilator support, is, in turn, the most lethal form of nosocomial pneumonia. The crude mortality rate associated with ventilatorassociated pneumonia has been estimated at up to 70% in diagnosed cases [2] . However, not all of these deaths are attributable solely to the infection itself. The actual mortality rate above that of ventilated patients with no infection has been estimated at approximately 30%, rising to approximately 40% in cases of pneumonia re-
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Nosocomial pneumonia is a major health problem, being associated with high morbidity, mortality, and healthcare costs. Diagnosis based on early symptoms or definitive diagnostic procedures is problematic, such that 30% of cases of nosocomial pneumonia are wrongly diagnosed. The spectrum of pathogens for nosocomial pneumonia differs from that for community-acquired pneumonia, with gram-negative bacteria such as Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii predominating. Antibiotic resistance is a considerable problem in these pathogens. The optimal approach to antibiotic therapy continues to be debated, although the need for early, aggressive empiric therapy is widely recognized. Initial empiric therapy for 3-4 days should be followed by pathogen-directed therapy, and initial intravenous therapy can be replaced with oral therapy after 7-14 days. The American Thoracic Society guidelines, published in 1995, assign patients to treatment options on the basis of the severity of illness, the time of onset relative to hospitalization, and the presence of risk factors. The ␤-lactam/␤-lactamase inhibitor combination cefoperazone/sulbactam offers good activity against Pseudomonas and multidrug-resistant gram-negative species, and is appropriate for use alone in patients with mild-to-moderate infections and in combination in patients with serious infections and risk factors. Clinical studies in Asia have documented the clinical effectiveness and safety of cefoperazone/sulbactam for the treatment of nosocomial pneumonia.
sulting from infection with either Pseudomonas aeruginosa or Acinetobacter species [2] . Ventilator-associated pneumonia also significantly extends the length of stay in the intensive care unit [1, 2, 4] .
Mirroring the situation observed among pathogens that cause community-acquired pneumonia, resistance among the causative agents of nosocomial pneumonia is an increasing problem. The prevalence of resistance to many of the commonly used antimicrobials in the intensive care unit is high [5] . Resistance to intensive care unit ␤-lactams and cephalosporins results largely from the increasing prevalence of plasmid-derived ␤-lactamases, which are freely transmissible [6] .
This article focuses on the etiology, diagnosis and treatment of nosocomial pneumonia, with reference to countries in Asia, in particular Thailand. The use of ␤-lactam/␤-lactamase inhibitor combinations in the treatment of nosocomial pneumonia in Asia and the existing American Thoracic Society (ATS) guidelines for the therapy of nosocomial pneumonia [4] are also reviewed.
Clinical Diagnosis
In the first instance, clinical diagnosis of nosocomial pneumonia is based on radiographic evidence of a new or progressive pulmonary infiltrate plus evidence that this infiltrate is of infectious origin. This evidence includes the presence of fever, leukocytosis, and purulent sputum or tracheobronchial secretions. If patients are treated at this stage of diagnosis, survival rates are good [4] .
A more definitive diagnosis can be obtained based on histopathologic examination of lung tissue, observation of rapid cavitation of lung infiltrate in radiographs, positive results from pleural fluid culture, or the isolation of pathogens from blood and sputum with no other identifiable source. Unfortunately, the delay involved in using these more definitive diagnostic measures results in much higher mortality rates, so treatment is typically initiated at the first suspicion of pneumonia [4] .
However, both diagnostic approaches present potential problems for accurate diagnosis. The early diagnostic approach may be too sensitive, whereas the more definitive diagnostic measures are costly, require skilled operators and specialized laboratories, and do not always produce accurate, definitive results. These inherent problems mean that a substantial number (approximately 30%) of diagnoses of nosocomial pneumonia are incorrect. The clinical symptoms that can lead to a diagnosis of pneumonia can result from noninfectious causes. One study demonstrated that fewer than one half of the patients diagnosed as having pneumonia by clinical signs produced positive cultures from samples collected by bronchoscopy [7] . Noninfectious conditions that can produce signs similar to those already described herein include congestive heart failure, atelectasis, pulmonary thromboembolism, and adult respiratory distress syndrome [3] .
Pathogens and Resistance
The spectrum of pathogens associated with nosocomial pneumonia differs from that for community-acquired pneumonia. It depends largely on the type of organisms colonizing the oropharynx, because microaspiration of upper airway secretions is the primary route of entry into the lower respiratory tract [4, 8] . Gram-negative bacteria, such as the Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii, are responsible for the majority of nosocomial pneumonia cases, with prevalence rates rising to almost 80% in some areas [9] . Resistance in these pathogens is a major problem. In some studies of gram-negative isolates, multidrug resistance (MDR) rates of 50% have been observed, whereas the frequency of extended spectrum ␤-lactamase producers has been estimated to be as high as 40% [9] .
Resistance to antibiotics is mediated by a number of mechanisms. The most common mechanism of resistance is the production of ␤-lactamases, which hydrolyze the ␤-lactam nucleus of penicillins and cephalosporins and so inactivate them. ␤-Lactam resistance can be mediated either chromosomally or via plasmids. At present, the primary ␤-lactam resistance mechanisms are plasmid mediated [10, 11] . This presents a major problem, because plasmids are mobile elements that are capable of transferring between organisms and are therefore able to transfer resistance genes. As a result, ␤-lactamases have become widespread among the gram-negative bacteria. The most recently recognized transferable ␤-lactamases are the extended spectrum ␤-lactamases [10] . These evolved from the earliest ␤-lactamases to be discovered (TEM-and SHV-type ␤-lactamases) and are capable of inactivating third-generation cephalosporins and monocyclic ␤-lactams [10] .
A review of resistance data from Asia and the Western Pacific has found numerous cases of extended spectrum ␤-lactamase-mediated resistance. In Australia, Malaysia, and Singapore, resistance to third-generation cephalosporins in Klebsiella pneumoniae is mediated by TEM/SHV. In Japan and Singapore, carbapenem resistance (carbapenemases) has been observed in P. aeruginosa and K. pneumoniae (Table 1 ) [11] . This is a significant problem in Japan, where many cases of community-acquired pneumonia are treated using carbapenems.
Patients with chronic obstructive pulmonary disease are at high risk of acquiring resistant microbial infections, and require aggressive therapy if nosocomial pneumonia develops. Data from the National Nosocomial Infections Surveillance System survey of resistance in nosocomial pneumonia pathogens revealed high levels of resistance in P. aeruginosa, Enterobacter, and K. pneumoniae (Table 2 ) [12] . In Asia, where ceftazidime is routinely used, there are significant levels of resistance among Enterobacter and K. pneumoniae isolates, which have culminated in high multidrug resistance rates and cross-resistance to third-generation cephalosporins and even ciprofloxacin [13] .
Principles of Antibiotic Therapy
The best strategy for the treatment of nosocomial pneumonia is a difficult matter, and the development of guidelines is problematic. The main hurdle to producing treatment guidelines for nosocomial pneumonia is that resistance levels among the causative agents vary considerably. To ensure that comprehensive coverage is achieved, the resultant guidelines would be very complex. However, it is generally agreed that initial empiric broad-spectrum antibiotic therapy to cover the most likely pathogens on day 1 is the first step (Table  3 ) [14, 15] . In the first few days, aggressive antibiotic therapy is needed. Prompt administration of the appropriate antimicrobial therapy is associated with improved outcomes.
Factors to be considered in selecting a treatment regimen include the severity of illness in the patient, any clue that might point to a specific pathogen, and the duration of hospital stay before the development of nosocomial pneumonia. As a general principle, therapy should be directed at the most prevalent and virulent pathogens. In cases of nosocomial pneumonia, this means using antimicrobial agents that are active against MDR pathogens, particularly gram-negative bacilli (e.g., Pseudomonas and Acinetobacter spp.) [14] .
Initial treatment for 3-4 days is followed by therapy that may be tailored to a specific pathogen, based on clinical data or microbiologic analysis of sputum or tracheal suction samples [15] . After 7-14 days, if the patient continues to demonstrate clinical improvement, the current intravenous therapy can be replaced by oral therapy with an agent that may or may not be the same as that administered intravenously. If improvement continues, the patient may be allowed to complete therapy at home. This has been shown to have benefits in terms of both cost reduction and increased patient satisfaction [16] .
The first few days of empiric antibiotic therapy are very important, and the aim should be to provide nearly 100% coverage of the most likely pathogens. Failure to use appropriate antibiotic therapy has serious consequences for mortality (Table 4) . Celis et al. [17] reported a mortality of 92% among patients with nosocomial pneumonia who received inappropriate therapy, compared with 31% among patients who received appropriate antibiotics. Both Torres et al. [18] ␤ and Kollef et al. [19] reported mortality rates of 52% among patients receiving inappropriate antimicrobials, compared with 23% and 12%, respectively, among those receiving appropriate therapy.
Guidelines for Nosocomial Pneumonia
There is currently only one set of published guidelines for nosocomial pneumonia, a situation that contrasts markedly with that for community-acquired pneumonia. These guidelines were published in 1995 by the ATS, and include a patient classification algorithm that is designed to direct physicians to appropriate therapies for particular patients [4] . However, these ATS guidelines have a high degree of complexity, with patients stratified according to disease severity, time of onset, and presence of risk factors. This complexityand the recommended treatments-have been the subject of some debate. For example, in the current treatment algorithm, patients with no risk factors and mild-to-moderate disease are classified in the same therapy group as those with severe disease (see Fig. 1 ).
For patients with mild-to-moderate disease, the recommended treatment is monotherapy with third-generation cephalosporins such as cefotaxime/ceftriaxone (Table 4 ) [4] . The same guidelines also state that patients with severe nosocomial pneumonia (associated with a mortality rate of more than 70%) will have been admitted to the intensive care unit and will have had respiratory failure, associated with severe sepsis and rapid radiographic progression. These patients would also receive the same therapy (Table 5 ) [4] . However, any monotherapy is unlikely to be successful, and is inadvisable. Although monotherapy is suitable for many patients, it provides no coverage for P. aeruginosa or MDR gramnegative bacteria. Combination therapy should always be used if P. aeruginosa or MDR bacteria are the suspected causative agents.
For mild-to-moderate infection or serious cases with no risk factors, ATS guidelines recommend monotherapy with cefotaxime, ceftriaxone, or a ␤-lactam/␤-lactamase inhibitor combination, such as ampicillin/sulbactam (Table 5 ). In serious cases with risk factors, monotherapy is inadequate. Recommended treatment is with ciprofloxacin or aminoglycoside in combination with a ␤-lactam/␤-lactamase inhibitor combination, an antipseudomonal penicillin, ceftazidime (which is still effective in some countries), or possibly, in serious cases, a carbapenem [4] . Vancomycin should be considered if methicillin-resistant Staphylococcus aureus is present. However, because gram-negative organisms, and not methicillin-resistant Staphylococcus aureus, are responsible for the majority of hospital-acquired pneumonia cases, vancomycin should not normally be used [4] .
In many countries, one of the more commonly used antibiotics in empiric therapy is a ␤-lactam with antipseudomonal activity, in particular ceftazidime. However, it has recently become clear that high levels of resistance in Klebsiella and Enterobacter spp. and Escherichia coli are a problem in some Asian countries, e.g., Thailand and Japan [13, 20] . This has made treatment of pseudomonal pneumonia with ceftazidime very difficult. As a result, many countries have switched in the last couple of years to empiric therapy with a ␤-lactam/␤-lactamase inhibitor combination with antipseudomonal activity, such as cefoperazone/sulbactam or piperacillin/tazobactam. The newer respiratory fluoroquinolones are also sometimes used, possibly in combination with an aminoglycoside or ciprofloxacin, to ensure activity against P. aeruginosa.
␤-Lactam/␤-Lactamase Inhibitor Combinations in Clinical Studies
␤-Lactam/␤-lactamase inhibitor combinations have demonstrated their efficacy against a range of pathogens in lower respiratory tract infections, especially against ␤-lactamase-producing strains, such as many strains of Haemophilus influenzae and Moraxella catarrhalis [21, 22] . In vitro studies have shown that the addition of a ␤-lactamase inhibitor to a ␤-lactam restores antimicrobial activity against pathogens that were resistant to the ␤-lactam alone [10] . Cefoperazone is a third-generation cephalosporin that is comparatively stable in the presence of ␤-lactamases of some Enterobacter spp. and has a wide spectrum of activity, including gram-negative aerobes and anaerobes [23] . It is also one of the few cephalosporins with activity against P. aeruginosa. When cefoperazone is combined with the ␤-lactamase inhibitor sulbactam, the combination is active against ␤-lactamaseproducing gram-positive staphylococci in addition to many of the gram-negative organisms with plasmidmediated ␤-lactamases [10] .
In many countries in Southeast Asia, cefoperazone has been widely used to treat nosocomial pneumonia, but resistance subsequently has become a problem after a number of years of use. In Thailand, 12% of hospitalized patients develop nosocomial infections, with nosocomial pneumonia accounting for 15% of these (1.8% of all hospitalized patients). In Thailand, and particularly in its large cities, nosocomial pneumonia is primarily caused by MDR gram-negative bacteria.
Given that cefoperazone/sulbactam offers good-toexcellent activity against MDR gram-negative strains in vitro [10] , we performed a study in three hospitals to assess its activity in a clinical setting [24] . We recruited 24 patients with nosocomial pneumonia. The most common causative agent was P. aeruginosa (37.5% of cases), followed by K. pneumoniae and Acinetobacter (16.7% each). The patients were treated with cefoperazone/sulbactam 1-2 g twice daily for a mean duration of 13 days.
The results of therapy were encouraging, with a clinical response being seen in 71% of patients (63% cure, 8% improvement; see Fig. 1 ). The microbiologic response showed eradication in 67%, persistence in 29%, and superinfection in only one patient (4%). The ATS guidelines suggest that ␤-lactam/␤-lactamase inhibitor combinations should be used for the empiric therapy of early-onset nosocomial pneumonia, whereas for lateonset pneumonia combination therapy is recommended [4] . However, given that in Thailand the most common pathogen in nosocomial pneumonia is P. aeruginosa (classified as a late-onset pathogen in the ATS guidelines), the rationale for using an antibiotic with antipseudomonal activity in Thailand is clear [24] .
In China, Li et al. [25] examined the efficacy of cefoperazone/sulbactam compared with the third-generation cephalosporin cefotaxime in a randomized, open-label study in the treatment of moderate-to-severe bacterial infection in hospitalized patients. Of the 207 patients enrolled in the study, 95 (46%) had a respiratory tract infection, of which 67 (70%) were pneumonia. In addition, the conditions of the trial stipulated that between one half and two thirds of the isolated pathogens should be [26] . A total of 514 patients enrolled in the study and received cefoperazone/sulbactam for a total of 673 episodes of fever. Of these 673 episodes, 83 (12.3%) were confirmed as resulting from nosocomial pneumonia. Cefoperazone/sulbactam was effective in treating these episodes, yielding a 61% success rate-similar to that in our later study [24] . Indeed, in many Southeast Asian countries, including Thailand, this combination is the first-line or second-line antibiotic therapy for febrile neutropenia. This study also demonstrated a low incidence of treatment-related adverse events (11%) [25] .
Conclusions
There are several key points to consider in the management of nosocomial pneumonia. Poor prognostic signs include respiratory failure, age more than 60 years, absence of leukocytosis, bilateral lung infiltrates, positive blood culture, and coexisting medical disease, particularly chronic obstructive pulmonary disease. Successful treatment depends on the prompt initiation of appropriate empiric antimicrobial therapy.
In many countries, especially in Southeast Asia, gram-negative bacteria are the most common causative agents of nosocomial pneumonia, and resistance to the commonly used antimicrobials, through either ␤-lactamase or MDR mechanisms, is likely. The initial empiric therapy should be broad-spectrum to cover all likely pathogens, until such time as a more definitive diagnosis can be made.
Not every case of nosocomial pneumonia responds to antimicrobials. If there is no response within 3 or 4 days, it is possible that the diagnosis is incorrect. There is evidence that diagnosis is not always straightforward and that other conditions can present similar symptoms. It is also possible that the initial antibiotic is not suitable, either because it does not have a sufficiently broad spectrum of activity or because the pathogen has developed resistance to the drug(s) used. In this case, an alternative must be used, because therapy with an unsuitable antibiotic is associated with a significant increase in the rate of mortality.
The need for clear guidance on therapeutic options is obvious. However, given the complicated nature of nosocomial infections and their therapy, a single set of guidelines, such as those published by the ATS, is likely to be unsuitable for use by all. Experience has demonstrated that there are large geographic differences in both etiology and patterns of resistance, and that what is appropriate in one country may not be so in another. The most effective guidelines are likely to be those that have been tailored to local conditions.
